 |
Clal Biotechnology Industries, driven by strategic vision and backed by significant financial resources, is Israel's largest life sciences investment group.
Clal Biotechnology Industries Ltd. (CBI) targets promising companies with innovative biopharmaceutical technologies and transforms them into viable, sustainable businesses. Managing over $600 million in capital, the Company successfully leverages a unique investment model of large-scale, long-term financial and managerial commitment that yields significant results and value creation.
CBI is held by Clal Industries & Investments Ltd. ("CII"; holding 59% of company's shares), a member of the IDB Group and one of Israel's largest investment companies, and Teva Pharmaceutical Industries Ltd. ("Teva"; holding 15% of company's shares), the world's largest manufacturer of generic drugs.
CBI is traded on the Tel Aviv Stock Exchange (TASE: CBI) and is included in the TA-100 Index. |
|
|
